NYMX
Nymox Pharmaceutical Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Market Cap: 22.5 Million
Primary Exchange: NASDAQ
Website: nymox.com
Shares Outstanding: 90.5 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2817 trading days
From: 2013-09-04 To: 2023-07-06
Lowest Point:
Nymox Pharmaceutical: Assessing The Short And Long Ideas
via: SeekingAlpha at 2019-06-13 15:14:00:000
Nymox Pharmaceutical ( NYMX ) has been accused of being an outright serial scam by well-known biopharma short expert Richard Pearson. This was from August 10, 2016, and he had this headline for his article - Nymox: This Offshore 'Biotech' Promotion Will Go To Zero (Yes, Zero). … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|